drugset / Trial / NCT00193284
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Phase 2
Completed
50 enrolled
SCRI Development Innovations, LLC
AstraZeneca · collabAventis Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited. In this trial, we will evaluate the feasibility, toxicity, and effectiveness a novel combination of chemotherapy, radiation therapy, and gefitinib.
Timeline
- Start
- 2003-10
- Primary completion
- 2006-02
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gefitinib | Small molecule | 250 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |